Prices are updated after-hours

Forma Therapeutics Holdings, Inc.

FMTX | $20.01 -0.15%

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar: 2022-11-09
Market Cap: $ 957,529,666
https://formatherapeutics.com
Sec Filling | Patents | 105 employees

Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of hematologic diseases and cancers. Its product pipeline consists of FT-4202 for the treatment of sickle cell disease and other hemoglobinopathies, and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company was founded by Michael A. Foley in December 2011 and is headquartered in Watertown, MA.

cancer prostate cancer t-cell treatment ceiling

add to watch list Paper trade email alert is off

Clovis Oncology, Inc.

CLVS | $0.0812 -3.94%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (26.22% volume)
Earnings Calendar: 2023-02-22
Market Cap: $ 11,770,367
http://www.clovisoncology.com
Sec Filling | Patents | 484 employees

Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of cancer treatments. Its marketed product Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is offered for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer; and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.

acquisitions cancer prostate cancer liver treatment cancer treatments

Drugs

Rubraca (rucaparib)

add to watch list Paper trade email alert is off

Nymox Pharmaceutical Corporation

NYMX | $0.2 -19.68% -23.88% 930K

Health Technology

(0.0% 1d) (0.0% 1m) (-50.5% 1y) (0.0% 2d) (-19.7% 3d) (0.0% 7d) (117.41% volume)
Earnings Calendar:
Market Cap: $ 18,103,028
http://www.nymox.com
Sec Filling | Patents | 4 employees

Nymox Pharmaceutical Corp. operates as a biopharmaceutical company, which engages in the research and development on products for the aging population. Its products include NicAlert and TobacAlert, and the NX-1207 for the treatment of low-grade localized prostate cancer. It operates through the following geographical segments: Canada, United States, and Europe. The company was founded by Paul Averback on May 30, 1995 and is headquartered in Nassau, the Bahamas.

cancer prostate cancer msa treatment 3d

add to watch list Paper trade email alert is off

PDS Biotechnology Corporation

PDSB | $2.855 -1.55% 240K

Health Technology

(0.0% 1d) (-39.7% 1m) (-54.0% 1y) (0.0% 2d) (6.6% 3d) (2.8% 7d) (84.66% volume)
Earnings Calendar: 2024-03-26
Market Cap: $ 104,719,330
http://www.pdsbiotech.com
Sec Filling | Patents | 20 employees

(United States) PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo on March 15, 2019 and is headquartered in Princeton, NJ.

covid breast cancer cancer prostate cancer immunotherapy injection

add to watch list Paper trade email alert is off

Bio-Techne Corp

TECH | $62.315 0.17% 190K

Health Technology

(0.0% 1d) (-12.7% 1m) (-23.5% 1y) (0.0% 2d) (0.0% 3d) (-4.3% 7d) (-44.13% volume)
Earnings Calendar: 2024-02-01
Market Cap: $ 9,795,399,851
http://www.bio-techne.com
Sec Filling | Patents | 2300 employees

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics &Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions, most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics &Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate(IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. The company was founded on 1976 and is headquartered in Minneapolis, MN.

cancer prostate cancer antibody molecular diagnostics multiplexing t-cell diagnostics msa ceiling

add to watch list Paper trade email alert is off

Autolus Therapeutics plc

AUTL | $4.73 -1.46% 99K

Health Technology

(0.0% 1d) (-25.8% 1m) (168.5% 1y) (0.0% 2d) (0.0% 3d) (-0.8% 7d) (-22.41% volume)
Earnings Calendar:
Market Cap: $ 1,257,831,423
http://autolus.com
Sec Filling | Patents | 292 employees

(United Kingdom) Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.

cancer prostate cancer t-cell treatment ceiling cancer treatments

add to watch list Paper trade email alert is off

BioXcel Therapeutics, Inc.

BTAI | $2.66 4.31% 240K

Health Technology

(0.0% 1d) (-8.3% 1m) (-87.9% 1y) (0.0% 2d) (0.0% 3d) (-7.3% 7d) (6.43% volume)
Earnings Calendar: 2024-03-12
Market Cap: $ 81,333,945
http://www.bioxceltherapeutics.com
Sec Filling | Patents | 24 employees

(United States) BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on drug development. The firm's two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.

cancer prostate cancer pancreatic neurological treatment

add to watch list Paper trade email alert is off

ESSA Pharma Inc.

EPIX | $6.9 2.68% 4.6K

Health Technology

(0.0% 1d) (-19.2% 1m) (168.2% 1y) (0.0% 2d) (0.0% 3d) (1.8% 7d) (-62.65% volume)
Earnings Calendar: 2024-02-06
Market Cap: $ 305,256,000
http://www.essapharma.com
Sec Filling | Patents | 25 employees

ESSA Pharma, Inc. engages in the development of small molecule drugs for prostate cancer. It focuses on producing drugs which selectively block the amino-terminal domain (NTD) of the androgen receptor (AR), potentially overcoming the known AR-dependent resistance mechanisms of castration-resistant prostate cancer (CRPC), and providing CRPC patients with the potential for increased progression-free and overall survival. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.

cancer prostate cancer molecule drugs

add to watch list Paper trade email alert is off

Kronos Bio, Inc.

KRON | $1.03 11K

Health Technology

(0.0% 1d) (-14.0% 1m) (-18.8% 1y) (0.0% 2d) (0.0% 3d) (-8.8% 7d) (-26.16% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 61,897,863
http://www.kronosbio.com
Sec Filling | Patents | 45 employees

Kronos Bio, Inc. is a clinical-stage biopharmaceutical, which engages in the provision of discovery and development of novel cancer therapeutics products. Its pipeline includes hematologic transcription factors, small cell, prostate cancer, and MYC-driven cancers. The company was founded by Angela Koehler and Joshua Kazam in 2017 and is headquartered in Cambridge, MA.

cancer prostate cancer myc-driven cancers t-cell ceiling

add to watch list Paper trade email alert is off

Lantheus Holdings, Inc.

LNTH | News | $63.115 1.26% 230K

Health Technology

(0.0% 1d) (5.3% 1m) (-30.4% 1y) (0.0% 2d) (0.3% 3d) (3.5% 7d) (Infinity% volume)
Earnings Calendar: 2024-02-22
Market Cap: $ 4,326,621,863
http://www.lantheus.com
Sec Filling | Patents | 508 employees

(US) Lantheus Holdings, Inc. engages in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its products are used by cardiologists, nuclear physicians, radiologists, internal medicine physicians, sonographers and technologists working in a variety of clinical settings. The firm operates through the following geographical segments: U.S. and International. The U.S. segment produces and markets medical imaging agents and products throughout the U.S. This segment sells its products to radio pharmacies, integrated delivery networks, hospitals, clinics and group practices. The International segment operations consist of production and distribution activities in Puerto Rico and direct distribution activities in Canada. The company was founded in 1956 and is headquartered in North Billerica, MA.

cardiovascular cardiologists diagnostics treatment nuclear prostate cancer

add to watch list Paper trade email alert is off

Veru Inc.

VERU | $1.365 -3.87% 1.7M

Health Technology

(0.0% 1d) (140.7% 1m) (18.3% 1y) (0.0% 2d) (22.4% 3d) (-7.2% 7d) (179.09% volume)
Earnings Calendar: 2024-02-08
Market Cap: $ 199,810,319
http://www.verupharma.com
Sec Filling | Patents | 386 employees

(United States) Veru, Inc. is an oncology and urology biopharmaceutical company. It develops medicines for prostate cancer treatment and prostate cancer supportive care as well as urology specialty pharmaceuticals. Its oncology drug candidates includes VERU-111, an oral alpha and beta tubulin inhibitor, which is in a phase 1b/2 study for the treatment of metastatic castration resistant prostate cancer; Zuclomiphene citrate, which is in a phase 2 clinical trial for the treatment of hot flashes in men undergoing prostate cancer hormonal therapies; and VERU-100, a long-acting GnRH antagonist 3 month subcutaneous depot, planned phase 2 clinical trial for the treatment of hormone sensitive advanced prostate cancer. The company’s urology specialty pharmaceutical drug candidate is TADFIN, a tadalafil and finasteride combination oral capsule, for the treatment of men with benign prostatic hyperplasia. Its commercial products include the FC2 Female/Internal condom for prevention of pregnancy and sexually transmitted infections and PREBOOST 4% benzocaine wipes for the prevention of premature ejaculation marketed as Roman Swipes by getroman.com. The company was founded by William R. Gargiulo Jr. and O.B. Parrish in 1996 and is headquartered in Miami, FL.

prostate cancer cancer hormone pregnancy clinical trials treatment corea cancer treatments injection

Drugs

Intimate Wipe (benzocaine)

add to watch list Paper trade email alert is off

Advaxis, Inc.

ADXS | $0.57 9.5K

Health Technology

(0.0% 1d) (-5.0% 1m) (-56.2% 1y) (0.0% 2d) (0.0% 3d) (-8.2% 7d) (94.57% volume)
Earnings Calendar: 2022-09-08
Market Cap: $ 24,301,038
http://www.advaxis.com
Sec Filling | Patents | 35 employees

(US) Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. It has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ.

cancer prostate cancer immunotherapy

add to watch list Paper trade email alert is off